All entries for: Prothena - Dublin

February 27, 2026

Prothena - Dublin

Neutral Outlook

Dublin, IE
51-200 employees

It is unclear how future regulatory actions to implement the IRA, as well as the outcome of pending litigation against the IRA brought against the Department of Health and Human Services (HHS), the Secretary of HHS, CMS, and the CMS Administrator challenging the constitutionality and administrative implementation of the IRA’s drug price negotiation provisions, may affect our products and future profitability.

Disease Area: Multiple, Neurological Diseases, Rare Diseases
Drug Type: Biologic, Small Molecule
June 23, 2025

Prothena - Dublin

Layoffs

Dublin, IE
51-200 employees

Just weeks after sharing that it was planning cost cuts that would include layoffs, Prothena has announced a 63% workforce reduction. That reduction likely includes the 91 people the Dublin-headquartered biotech disclosed it was letting go in Brisbane, California, via a Worker Adjustment and Retraining Notification notice earlier this month.

Disease Area: Multiple, Neurological Diseases, Rare Diseases
Drug Type: Biologic, Small Molecule
Scroll to Top